Zoetis Inc. (NYSE:ZTS) shares hit a new 52-week high on Friday . The company traded as high as $50.54 and last traded at $50.40, with a volume of 1,615,163 shares. The stock had previously closed at $50.06.

ZTS has been the topic of a number of recent analyst reports. Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $53.00 price objective on the stock in a report on Monday, May 9th. Jefferies Group reaffirmed a “buy” rating on shares of Zoetis in a report on Sunday, May 8th. Stifel Nicolaus initiated coverage on Zoetis in a report on Tuesday, May 31st. They set a “buy” rating and a $58.00 price objective on the stock. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Zoetis in a report on Sunday, May 22nd. Finally, Guggenheim reaffirmed a “buy” rating and set a $60.00 price objective on shares of Zoetis in a report on Monday, July 18th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $54.68.

The firm has a market cap of $25.04 billion and a PE ratio of 66.58. The firm has a 50-day moving average of $48.27 and a 200-day moving average of $45.45.

Zoetis (NYSE:ZTS) last announced its earnings results on Wednesday, May 4th. The company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.07. During the same period in the previous year, the firm earned $0.41 EPS. The business had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.10 billion. The firm’s revenue was up 5.4% on a year-over-year basis. Analysts predict that Zoetis Inc. will post $1.87 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, August 30th. Shareholders of record on Thursday, June 30th will be paid a dividend of $0.095 per share. This represents a $0.38 annualized dividend and a yield of 0.75%. The ex-dividend date of this dividend is Tuesday, June 28th.

In other Zoetis news, Director Pershing Square Capital Manage sold 16,850,000 shares of Zoetis stock in a transaction on Monday, May 9th. The stock was sold at an average price of $46.55, for a total transaction of $784,367,500.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

A number of hedge funds have made changes to their positions in ZTS. Baker Chad R acquired a new stake in shares of Zoetis during the fourth quarter valued at $1,189,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in shares of Zoetis by 5.5% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 31,129 shares of the company’s stock valued at $1,492,000 after buying an additional 1,636 shares during the period. Greenwood Capital Associates LLC purchased a new position in shares of Zoetis during the fourth quarter valued at about $1,532,000. Advantus Capital Management Inc boosted its position in shares of Zoetis by 2.6% in the fourth quarter. Advantus Capital Management Inc now owns 44,257 shares of the company’s stock valued at $2,121,000 after buying an additional 1,110 shares during the period. Finally, Pittenger & Anderson Inc. boosted its position in shares of Zoetis by 5.1% in the fourth quarter. Pittenger & Anderson Inc. now owns 53,605 shares of the company’s stock valued at $2,569,000 after buying an additional 2,600 shares during the period.

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.